Arbutus Biopharma
ABUS
65 hedge funds and large institutions have $75.5M invested in Arbutus Biopharma in 2020 Q3 according to their latest regulatory filings, with 30 funds opening new positions, 9 increasing their positions, 16 reducing their positions, and 16 closing their positions.
88% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 16
59% more capital invested
Capital invested by funds: $47.6M → $75.5M (+$28M)
27% more funds holding
Funds holding: 51 → 65 (+14)
8.76% less ownership
Funds ownership: 37.88% → 29.12% (-8.8%)
20% less call options, than puts
Call options by funds: $1.5M | Put options by funds: $1.87M
44% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 16
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCMI
Foresite Capital Management IV
Larkspur,
California
|
+$10.1M |
| 2 |
TI
Think Investments
San Francisco,
California
|
+$6.08M |
| 3 |
BlackRock
New York
|
+$2.53M |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
+$1.99M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.26M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAC
Cowen and Company
New York
|
-$11.7M |
| 2 |
Goldman Sachs
New York
|
-$4.29M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$3.89M |
| 4 |
RI
RTW Investments
New York
|
-$2.71M |
| 5 |
Morgan Stanley
New York
|
-$1.35M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CB
76
CNB Bank
Clearfield,
Pennsylvania
| – | -$2K | -1,045 | Closed |
|
77
BNP Paribas Financial Markets
Paris,
France
| – | -$11 | -6 | Closed |
|
ABUS Hedge Fund Activity: Q3 2020 in Review
65 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Arbutus Biopharma (ABUS) for Q3 2020, worth a combined $75.5M — up 59% from $47.6M a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new ABUS positions and 16 closed out — a net gain of 14 holders — while 9 added to existing stakes and 16 trimmed.
The largest buyer was Foresite Capital Management IV, opening a new position worth an estimated $10.1M. The largest seller was Cowen and Company, cutting an estimated $11.7M.
- 65 institutional investors held Arbutus Biopharma (ABUS) as of Q3 2020, up from 51 in Q2 2020.
- Funds reported $75.5M of Arbutus Biopharma stock for Q3 2020, up 59% quarter-over-quarter.
- 30 funds opened new Arbutus Biopharma positions in Q3 2020 and 16 closed out, a net change of +14 holders.
- The largest Arbutus Biopharma buyer in Q3 2020 was Foresite Capital Management IV, an estimated $10.1M added.
- The largest Arbutus Biopharma seller in Q3 2020 was Cowen and Company, an estimated $11.7M sold.
Based on aggregated 13F filings for Q3 2020.